Search
Without access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
EHA-SSH Joint membership
We are pleased to inform that EHA and the Swiss Society of Hematology (SSH) have joined forces and are offering you the possibility of an EHA-SSH Joint Membership in 2023.
Read moreIMI2 Call for Research Proposals
The indicative budget for this topic is 40 million Euro, half of which by way of an in kind contribution from Industry Consortium EFPIA (European Federation of Pharmaceutical Industries and Associations) companies.
Read moreSelected EMA news
September 2024Safety update
Withdrawal of Oxbryta (Voxelotor) – marketing authorisation suspended
Treatment of haemolytic anaemia (excessive breakdown of red blood cells) due to sickle cell disease
New medicines approved
Adzynma (rADAMTS13) - orphan medicine
Treatment of congenital thrombotic thrombocytopenic purpura (an inherited clotting disorder)
Other…
Uptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read moreEHA-AAH Joint membership
We are pleased to inform that EHA and the Albanian Association of Hematology (AAH) have joined forces and are offering you the possibility of an EHA-AAH Joint Membership in 2023.
Read moreEHA-AHA Joint membership
We are pleased to inform that EHA and the Armenian Hematology Association (AHA) have joined forces and are offering you the possibility of an EHA-AHA Joint Membership in 2023.
Read more